Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes
Key facts
- Where
- Bern, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT06282055, who can take part
Where in Switzerland
- DCB Research AGBern, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- DCB Research AG
- Trial code
- NCT06282055
- Record updated
- 3 December 2025
- Original description
Standardized longitudinal data collection of diabetes management relevant factors in women with T1D (insulin requirements, glucose variability, nutritional information, and menstrual cycle information) to identify categories of cycle trajectories.Read full original descriptionShow less
Trajectories in Insulin Sensitivity Across Menstrual Cycles in Women With Type 1 Diabetes
Standardized longitudinal data collection of diabetes management relevant factors in women with T1D (insulin requirements, glucose variability, nutritional information, and menstrual cycle information) to identify categories of cycle trajectories.
Inclusion: Female sex; Between 18 and 40 years at inclusion; Menarche at least one year prior to study inclusion; Regular menstrual cycle (at least one menstrual cycle in the last 40 days); Average menstrual cycle length between 21 and 38 days; Difference in length between consecutive menstrual cycles of at most 7 days; Living with type 1 diabetes or latent autoimmune diabetes in adults (LADA) for at least one year; Actively using an AID system for their diabetes management at least six months prior to study inclusion.
Exclusion: Regular hormonal intake (e.g. corticosteroids), except: insulin, stable thyroid substitution, and hormonal contraception; Intake of glucocorticoid medication, agents affecting gastric emptying, oral anti-diabetic agents (Metformin) or SGLT-2 inhibitors or GLP-1-analogs; Known Polycystic Ovary Syndrome (PCOS); Pregnancy until two months postpartum (ongoing or planned); Current breastfeeding (including pumping), as well as two months following complete cessation of breastfeeding and pumping; Individuals with work patterns involving frequent shifts between night and day work (e.g., alternating night and day shifts on a weekly or similar basis); Participation in an interventional study within two months preceding and during the present study.